Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Structure Therapeutics reported that its new weight loss pill produced a 16.3% drop in body weight. Patients taking the 180 mg daily dose lost about 39 pounds over 44 weeks. Notably, the study found that patients kept losing weight throughout the entire trial. These results show a clear improvement over the earlier data shared in late 2025.
The trial results put aleniglipron in a strong position against current weight loss shots. Two large companies currently lead the market with injectable drugs. In light of this, a different oral drug from another company showed only 12% weight loss in similar tests. Analysts now believe this new pill might be the best oral option in development.
Safety and comfort results also backed up the strong weight loss numbers. Researchers watched closely to see if patients stopped the drug or felt sick. Along with this, experts looked at these side effects for those on the highest doses. One expert noted that the drug is very competitive since fewer people stopped treatment.
The 180 mg dose seems like a solid choice for long term use. The world of weight loss medicine is seeing a major shift right now. Shots have been the main choice for several years. Nevertheless, pills are easier to make and much simpler for patients to take every day.
Drug companies are now putting more money into oral weight loss programs. These businesses want to win a share of this growing medical market. Furthermore, many people simply prefer a pill over a needle. This change marks a new era for the global medicine industry.
Structure Therapeutics plans to start a final large scale study in late 2026. The company leaders are already talking with potential partners and buyers. Building on this, one analyst said the trial results make the company a top target for a merger. The news caused the company stock price to jump by about 9%.
One industry expert mentioned that these results set a record for weight loss pills. This performance puts the pill on the same level as the leading shots. Accordingly, injectable drugs currently set the bar for how well these medicines should work. The company must still prove these results hold up in a much larger group of people.
The upcoming phase 3 program will be the next big step for the drug. This data will eventually go to federal health officials for a formal review. Moreover, the study must prove the drug is safe for long term use. Therefore, the company is carefully planning its timeline for these important regulatory steps.
Future tests will look at how the drug works for different types of people. This work ensures the safety data meets high national health standards. Consequently, doctors are very interested to see what happens in the next round of testing. Success here could change how we treat weight issues for good.
Health systems like oral drugs because they can help lower long term costs. Doctors also expect patients to stay on their medicine longer with a simple daily pill. Thus, the medical community sees aleniglipron as a potential game changer. Ongoing checks will focus on how long the weight loss lasts over several years.
